Clinical Trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.
Protocol Amendment History 1 change
notable Trial sites expanded: 32 -> 35 locations 2026-05-06
Trial Details
NCT Number NCT06343402
Lead Sponsor TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Conditions Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C, Metastatic Lung Cancer, Advanced Lung Carcinoma
Enrollment 350 participants
Start Date 2024-05-22
Primary Completion 2031-04 (estimated)
Study Completion 2031-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-05